SLNO
$33.62
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of ...
Recent News
H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) from $120 to $100, while maintaining a Buy rating on the shares. The rating follows the company’s fiscal Q4 […]
Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy
Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most shorted stocks to buy according to analysts. On February 25, Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted strong financial results for the fourth quarter of 2025, exceeding Wall Street estimates with EPS of $0.80, up from $0.61. Revenue also exceeded expectations, totaling $91.7 million compared to an expected $82.45 […]
Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here’s Why
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best cheap biotech stocks to buy now. Wells Fargo cut the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $110 from $114 on February 27, reaffirming an Overweight rating on the shares and stating that while some investors’ near-term takeout thesis may be removed by the management’s […]
Soleno Profitability Milestone And CFO Shift Raise Valuation Questions
Soleno Therapeutics (NasdaqCM:SLNO) reports achieving full year profitability within nine months of launching its lead rare disease product, VYKAT XR. The company announces an executive transition, with longtime CFO James Mackaness retiring and Jennifer Fulk appointed as the new Chief Financial Officer. Fulk joins Soleno from a multinational pharmaceutical background as the company pursues EU regulatory approvals and advances its pipeline. For investors watching rare disease biotech,...
Sector Update: Health Care Stocks Lower in Late Afternoon Trading
Health care stocks declined late Thursday afternoon with the NYSE Health Care Index easing 0.1% and